Epizyme, Inc. (EPZM)

Oncology Corporate Profile

Stock Performance

16.6500
0.0500

HQ Location

400 Technology Square 4th Floor
Cambridge, MA 02139

Company Description

Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression.

Website: http://www.epizyme.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
tazemetostatEZH2 inhibitorDiffuse large B-cell Lymphoma (DLBCL)II
EPZ-6438EZH2 inhibitorNon-Hodgkin's Lymphoma (NHL)II
tazemetostatEZH2 inhibitorSarcomaII
EPZ-5676DOT1L inhibitorAcute Myelogenous Leukemia (AML)I

View additional information on product candidates here »

Pipeline image

Source


http://www.epizyme.com

Recent News Headlines

EPIZYME, INC. Financials

3/16/2017 05:00 pm

Epizyme reports 4Q loss

3/9/2017 11:04 am

Epizyme reports 4Q loss

3/9/2017 11:04 am

Epizyme President of Research and Chief Scientific Officer, Robert Copeland, Announces Retirement from the Company

3/9/2017 11:03 am

[GlobeNewswire] - CAMBRIDGE, Mass., March 09, 2017-- Epizyme, Inc., a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that President of Research and Chief Scientific Officer, ...

Epizyme Reports 2016 Financial Results and Provides 2017 Pipeline Goals

3/9/2017 11:03 am

[GlobeNewswire] - Data from Tazemetostat Phase 2 Programs in NHL and Molecularly Defined Solid Tumors Planned for Medical Meetings in Second Quarter. Conference Call to Be Held Today at 8:30 a.m. Eastern Time. CAMBRIDGE, ...

Epizyme Announces 2016 Fourth Quarter and Full-Year Results Conference Call Date and March Investor Conferences

2/27/2017 02:00 pm

[GlobeNewswire] - CAMBRIDGE, Mass., Feb. 27, 2017-- Epizyme, Inc., a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will host a conference call and webcast ...

Epizyme Elects Kevin Conroy to its Board of Directors

2/7/2017 11:03 am

[GlobeNewswire] - CAMBRIDGE, Mass., Feb. 07, 2017-- Epizyme, Inc., a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the Company has elected industry veteran Kevin Conroy, ...

Epizyme to Present at Upcoming Investor Conferences

2/2/2017 11:03 am

[GlobeNewswire] - CAMBRIDGE, Mass., Feb. 02, 2017-- Epizyme, Inc., a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the Company will present at the following investor ...